X4 Pharmaceuticals, Inc

# Signal Note: BVF Partners Initiates X4 Pharmaceuticals Position BVF's $8.9M entry into XFOR signals conviction in the company's lead asset mavorixafor (CXCL12 antagonist) for WHIM syndrome, a rare immunodeficiency with limited treatment options and potential for accelerated approval pathways. The timing aligns with pending regulatory catalysts, likely including FDA decisions on the WHIM indication and potential label expansion into other neutrophil disorders. Lampert's value-focused thesis typically targets mispriced biotech with clear paths to profitability, suggesting he sees meaningful upside if clinical/regulatory execution materializes.